Rosa Lapalombella

Rosa Lapalombella's research focuses on blood cancers, especially chronic lymphocytic leukemia, lymphoma, and acute leukemias, with an emphasis on understanding how mutations and protein regulation drive disease progression and drug resistance. A major thread of the work involves the protein export receptor XPO1/CRM1 and related compounds (SINE/selinexor) as well as NAMPT inhibitors, aiming to identify new drug combinations and overcome resistance to therapies such as venetoclax. This work is largely translational, combining laboratory studies of cancer cell mechanisms with clinical and drug-repurposing angles.

Publication output has grown substantially over the past decade, rising from single digits annually before 2019 to a sharp peak of 64 in 2023 and remaining high (16-23 per year) through 2024-2026.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026